EAU 2013 - Programme Book - YouMed

Monday
Monday, 18 March - EAU Programme
11.00 - 12.00 Andrology
256 Programme Book
Thematic Session 10
eURO Auditorium - Level S2
Chair: J.O.R. Sonksen, Herlev (DK)
11.00 - 11.15 State-of-the-art lecture Modern management of ejaculatory disorders
A. Salonia, Milan (IT)
Aims and objectives
Despite copious findings on the physiology of ejaculation, as well as on the pathophysiology of Premature
Ejaculation (PE), treatment of early ejaculation is still not well-outlined, with only a minor proportion of
patients complaining of primary PE being actively treated. These discrepancies may be considered as the
unfortunate result of a combination of several factors: 1) PE per se is often underdiagnosed in clinical
practice; 2) Urologists do not follow the guidelines for the treatment of PE in their everyday clinical practice;
3) The lack of a widely recognised gold standard treatment, as well as the presence of a number of potential
side effects which characterise almost all the compounds available for PE. In this context, off-label daily
dosing of paroxetine, sertraline, citalopram, fluoxetine, or clomipramine are regarded as first line treatments
for PE worldwide. Recently, dapoxetine hydrochloride - a short-acting SSRI with a pharmacokinetic profile
favourable for on-demand treatment of PE has been launched on the market as the first on-demand and
on-label treatment for PE.
11.15 - 11.30 State-of-the-art lecture Current treatment possibilities for erectile dysfunction
I. Eardley, Leeds (GB)
Aims and objectives
This lecture will discuss new treatment options for a man with erectile dysfunction and will critically evaluate
the evidence for these therapies. The discussion will include both medical and physical therapies.
11.30 - 11.45 State-of-the-art lecture Developments in the diagnosis and therapy of priapism
A. Muneer, London (GB)
Aims and objectives
This session will aim to highlight the recent developments in diagnostic imaging and surgical interventions
for the three sub-types of priapism; ischaemic, non-ischaemic and stuttering.
Both clinical studies and in vitro studies have helped to formulate novel theories in order to explain the
development of priapism and suggest effective management strategies. For a long time, the management of
priapism has been based on anecdotal reports and therefore therapeutic guidelines vary globally. The use of
both in vivo and in vitro models of priapism have now helped our understanding of the pathophysiology of
this condition and helped develop alternative therapeutic interventions, particularly in the area of refractory
ischaemic priapism and stuttering priapism. By understanding the fundamental changes at a molecular
level, clinicians will be able to develop an evidence based treatment algorithm for difficult cases
11.45 - 12.00 Abstract presentations: Special selection from the poster sessions
324 Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with
improved erectile function in a rat model of Peyronie’s disease
F. Castiglione, P. Hedlund, F. Van Der Aa, T.J. Bivalacqua, M. Albersen (Milan, Italy; Leuven, Belgium;
Baltimore, United States of America)